Summary
Ten human leukemia-lymphoma cell lines were tested for the growth-inhibitory effects of harringtonine (HT). HT was most active against HL-60 acute promyelocytic leukemia cells and least active against DND-41 acute lymphoblastic leukemia cells, with a 70-fold differential activity. Sensitivity of the cell lines is, in decreasing order: HL-60 > RPMI-8402 > DND-39A ≃ ML-2 ≃ MOLT-3 ≃ KG-1 > Daudi ≃ NALL-1 > BALM-2 > DND-41. The cell lines with rapid cell growth tended to be more sensitive to HT. To further elucidate the selectivity of the differential sensitivity, uptake and release of HT were compared in HL-60 and DND-41 cells. Uptake of [3H]HT into HL-60 and DND-41 cells showed no difference; however, the binding of [3H]HT to cellular components was > 16-fold higher in HL-60 cells than DND-41 cells. There were also minor, but significant differences in the inhibition of [3H]leucine incorporation into proteins of these two cell lines in the presence of 1 μg/ml HT. To test whether the biological effects of HT are related to the concentration of, or exposure time to, HT, KG-1 cells were exposed to HT for different periods of time and the growth-inhibitory effects were compared. Increasing exposure time from 1 h to 3 h resulted in a 100-fold decrease in concentration x exposure time (c x t) at ID50; from 3 h to 6 h, in a 20-fold decrease at ID70; and from 6 h to 24 h, in a 16-fold decrease at ID90. HT was not inactivated by cells up to 24 h. These results indicate that (a) the sensitivity of different cell lines to HT may be related to the degree of HT binding; and (b) the effects of HT are more dependent on exposure time than concentration. Continuous infusion is thus rational for clinical trials of this drug, and the degree of HT binding to leukemic cells may be predictive of clinical response.
Similar content being viewed by others
References
Alberts DS, Chen HSG, Salmon SE (1980) In vitro drug assay: Pharmacologic consideration. In: Salmon SE (ed) Cloning of human tumor stem cells. Liss, New York, pp 197–207
Aldrich CD (1979) Pleiotropic phenotype of cultured murine cells resistant to maytansine, vincristine, colchicine and adriamycin. J Natl Cancer Inst. 63:751–757
Cephalotaxus Research Coordinating Group (1976) Chephalotaxine esters in the treatment of acute leukemia. A preliminary clinical assessment. Chinese Med J 2:263–272
Chinese People's Liberation Army 187th Hospital (1977) Harringtonine in acute leukemias. Clinical analysis of 31 cases. Chinese Med J 3:319–324
Chou TC, Burchenal JH, Fox JJ, Watanabe KA, Chu CK, Philips FS (1979) Metabolism and effects of 5-(β-d-ribofuranosyl) isocytosine in P815 cells. Cancer Res 39:720–728
Chou TC, Schmid FA, Feinberg A, Philips FS, Han J (1983) Uptake, initial effects and chemotherapeutic efficacy of harringtonine in murine leukemic cells sensitive and resistant to vincristine and other chemotherapeutic agents. Cancer Res 43:3074–3079
Clinical Brochure (1981) Homoharringtonine (NSC-141633). National Cancer Institute, Bethesda
Collins SJ, Gallo RC, Gallagher RE (1977) Continuous growth and differentiation of human myeloid leukemic cells in suspension culture. Nature 270:347–349
Coonley CJ, Warrell RP Jr, Young CW (1983) Phase I trial of homoharringtonine administered as a 5-day continuous infusion. Cancer Treat Rep 67:693–696
Dano K (1972) Cross resistance between vinca alkaloids and anthracyclines in Ehrlich ascites tumor in vivo. Cancer Chemother Rep 56:701–708
Hematology Research Division and Hematology Section of the Children's Hospital, Suzhou Medical College (1980) High remission induction (traditional Sino-Western HOAP) regimen for acute nonlymphocytic leukemia. Chinese Med J 93:565–568
Huang MT (1975) Harringtonine, an inhibitor of initiation of protein biosynthesis. Mol Pharmacol 11:511–519
Koeffler HP, Golde DW (1978) Acute myolegenous leukemia: A human cell line responsive to colony-stimulating activity. Science 200:1153–1154
Melamud SC, Ohnuma T, Coffey V, Paciucci PA, Wasserman LR, Holland JF (1984) Phase I study of homoharringtonine in 10 day schedule: 6 h infusion daily vs continuous infusion. (Abstract) Proc Am Assoc Cancer Res 25:179
Mellett LB (1974) The constancy of the product of concentration and time. In: Santorelli AC, Johns DC (eds) Antineoplastic and immunosuppressive agents, part 1. Springer New York Heidelberg Berlin, pp 330–340
Minowada J, Ohnuma T, Moore GE (1972) Rosette-forming human lymphoid cell lines. I. Establishment and evidence for origin of thymus-derived lymphocyte. J Natl Cancer Inst 49:891–895
Minowada J, Oshimura M, Tsubota T, Higby DJ, Sandberg AA (1977) Cytogenetic and immunoglobulin markers of human leukemic B-cell lines. Cancer Res 37:3096–3099
Minowada J, Sagawa K, Lok MS, Kobonishi I, Nakazawa S, Tatsumi E, Ohnuma T, Goldblum N (1980) A model of lymphoid-myeloid cell differentiation based on the study of marker profiles of 50 human leukemia-lymphoma cell, lines. In: Serrou B, Rosenfeld C (eds) International Symposium of New Trends in Human Immunology and Cancer Immunotherapy. Doin, Paris, pp 188–199
Miyoshi I, Hiraki S, Tsubota T, Kubonishi I, Matsuda Y, Nakayama T, Kishimoto H, Kimura I, Masuji H (1977) Human B cell, T cell and null cell leukaemic cell lines derived from acute lymphoblastic leukaemias. Nature 267:843–844
Moore GE (1975) Cell lines from humans with hematopoietic malignancies. In: Fogh J (ed) Human cells in vitro. Plenum, New York, pp 299–331
Nodkarni JS, Nodkarni JJ, Clifford P, Manolov G, Fenyö EM, Klein E (1969) Characteristics of new cell lines derived from Burkitt lymphomas. Cancer 23:64–79
Neidhart JA, Young DC, Derocher D, Metz EN (1983) Phase I trial of homoharringtonine. Cancer Treat Rep 67:801–804
Ohnuma T, Arkin H, Holland JF (1980) Differences in chemotherapeutic susceptibility of human T-, B- and non-T/non-B lymphocytes in culture. Recent Results Cancer Res 75:61–67
Ohnuma T, Arkin H, Takahashi I, Andrejczuk A, Roboz J, Holland JF (1982) Biochemical bases of the differential susceptibility of malignant immune cells to asparaginase and to cytosine arabinoside. In: Arnott MS, Eys JV, Wang YM (eds) Molecular interrelations of nutrition and cancer. Raven, New York, pp 105–121
Okano T, Ohnuma T, Holland JF, Koeffler HP, Han J (1983) Effects of harringtonine in combination with acivicin, adriamycin, l-asparaginase, cytosine arabinoside, dexamethasone, fluorouracil or methotrexate on human acute myelogenous leukemia cell line KG-1. Invest New Drugs 1:145–150
Powell RG, Weisleder D, Smith CR Jr, Wolff IA (1969) Structure of cephalotaxine and related alkaloids. Tetrahedron Lett 4081–4084
Powell RG, Weisleder D, Smith CR Jr, Rohwedder WK (1970) Structure of harringtonine, isoharringtonine and homoharringtonine. Tetrahedron Lett 815–818
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Takemura, Y., Ohnuma, T., Chou, TC. et al. Biologic and pharmacologic effects of harringtonine on human leukemia-lymphoma cells. Cancer Chemother. Pharmacol. 14, 206–210 (1985). https://doi.org/10.1007/BF00258117
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00258117